CLL Coverage from Every Angle

Can a Third Dose of COVID-19 Vaccine Produce Antibodies in Seronegative Patients With CLL?

By: Emily Rhode
Posted: Thursday, December 23, 2021

A recent study suggested that some patients with chronic lymphocytic leukemia (CLL) who failed to respond to two COVID-19 mRNA vaccination doses may be more likely to develop an adequate antibody response following a third COVID-19 vaccination dose. Ohad Benjamini, MD, of the Sheba Medical Center, Ramat Gan, Israel, and colleagues published the results of this study in the journal Blood.

In the 172-patient study, seronegative patients with CLL or small lymphocytic leukemia were selected to give blood samples 3 weeks after their third dose of the BNT162b2 vaccine. Blood samples were analyzed for spike-specific IgG antibodies. Of the 172 patients, 23.3% were not receiving treatment for CLL, 58.1% were on active therapy, and 18.6% were previously treated.  

An antibody response was seen in 41 of 172 patients (23.8%). These patients had a median antibody titer of 2 AU/mL. In treatment-naive and off-treatment patients, response rates were higher [40% (16 of 40) and 40.6% (13 of 32, respectively)], compared with actively treated patients (12%, 12 of 100).

Higher levels of anti–SARS-Cov-2S–receptor binding domain IgG titers were associated with patients aged 65 or younger, a lack of active treatment, and higher serum IgG and IgA levels. Additionally, Bruton’s tyrosine kinase inhibitors or venetoclax with or without anti-CD20 treatments were linked to poor antibody response; 1 of 28 patients treated with anti-CD20 antibodies less than 12 months before vaccination had an antibody response.

“These findings are of practical importance, as they show that a third dose can still achieve seroconversion, even in the more immunosuppressed subgroup of patients with CLL,’” they concluded.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.